Profile data is unavailable for this security.
About the company
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
- Revenue in USD (TTM)55.28m
- Net income in USD-160.66m
- Incorporated2017
- Employees245.00
- LocationAlector Inc131 OYSTER POINT BLVD., SUITE 600SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (415) 231-5660
- Fax+1 (302) 655-5049
- Websitehttps://alector.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celcuity Inc | 0.00 | -82.59m | 562.49m | 55.00 | -- | 3.18 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Arcturus Therapeutics Holdings Inc | 163.87m | -71.96m | 568.43m | 180.00 | -- | 2.20 | -- | 3.47 | -2.68 | -2.68 | 6.11 | 9.56 | 0.40 | -- | 12.19 | 910,366.70 | -17.57 | -19.66 | -22.59 | -24.90 | -- | -- | -43.92 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Q32 Bio Inc | 0.00 | -65.02m | 568.86m | 41.00 | -- | 16.88 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
Tourmaline Bio Inc | 0.00 | -35.69m | 579.49m | 44.00 | -- | 1.71 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Alector Inc | 55.28m | -160.66m | 597.55m | 245.00 | -- | 3.97 | -- | 10.81 | -1.81 | -1.81 | 0.6162 | 1.55 | 0.0864 | -- | -- | 226,536.90 | -25.11 | -20.00 | -32.15 | -23.81 | -- | -- | -290.66 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
Mineralys Therapeutics Inc | 0.00 | -119.67m | 601.69m | 28.00 | -- | 2.07 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Third Harmonic Bio Inc | 0.00 | -32.74m | 605.37m | 42.00 | -- | 2.34 | -- | -- | -0.8204 | -0.8204 | 0.00 | 6.31 | 0.00 | -- | -- | 0.00 | -11.87 | -- | -12.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
Lenz Therapeutics Inc | 0.00 | -72.31m | 607.13m | 6.00 | -- | 2.96 | -- | -- | -9.45 | -9.45 | 0.00 | 7.46 | 0.00 | -- | -- | 0.00 | -29.53 | -- | -30.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Allogene Therapeutics Inc | 65.00k | -279.42m | 608.51m | 232.00 | -- | 1.18 | -- | 9,361.76 | -1.59 | -1.59 | 0.0004 | 2.46 | 0.00009 | -- | -- | 280.17 | -39.41 | -28.46 | -42.15 | -30.21 | -- | -- | -429,881.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Lexicon Pharmaceuticals Inc | 3.64m | -202.11m | 610.92m | 285.00 | -- | 2.55 | -- | 167.79 | -0.7783 | -0.7783 | 0.0139 | 0.6639 | 0.0106 | 0.7239 | 2.20 | 12,775.44 | -58.57 | -24.41 | -63.55 | -29.01 | 92.47 | 98.49 | -5,550.87 | -84.92 | 11.49 | -11.96 | 0.2931 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
Regenxbio Inc | 89.04m | -241.08m | 617.79m | 344.00 | -- | 1.77 | -- | 6.94 | -5.27 | -5.27 | 1.93 | 7.06 | 0.1423 | -- | 4.03 | 258,848.80 | -38.52 | -16.75 | -46.55 | -19.08 | 56.78 | 78.27 | -270.74 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
Alumis Inc | -100.00bn | -100.00bn | 618.57m | 128.00 | -- | -- | -- | -- | -- | -- | -- | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
Corbus Pharmaceuticals Holdings Inc | 0.00 | -34.97m | 622.67m | 19.00 | -- | 4.74 | -- | -- | -5.82 | -5.82 | 0.00 | 10.92 | 0.00 | -- | -- | 0.00 | -35.74 | -86.84 | -45.03 | -130.46 | -- | -- | -- | -769.76 | -- | -29.78 | 0.0794 | -- | -- | -- | -5.33 | -- | -- | -- |
Y-mAbs Therapeutics Inc | 86.55m | -24.61m | 623.98m | 100.00 | -- | 6.54 | -- | 7.21 | -0.5618 | -0.5618 | 1.98 | 2.14 | 0.6262 | 1.42 | 4.19 | 865,460.00 | -17.81 | -44.23 | -23.58 | -50.45 | 88.74 | -- | -28.44 | -181.13 | 2.72 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 14.46m | 14.86% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 6.68m | 6.87% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 5.12m | 5.26% |
Deep Track Capital LPas of 30 Jun 2024 | 4.63m | 4.76% |
Morgan Stanley & Co. LLCas of 30 Jun 2024 | 2.86m | 2.94% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.79m | 2.87% |
Braidwell LPas of 30 Jun 2024 | 2.38m | 2.45% |
Soleus Capital Management LP (Investment Management)as of 30 Jun 2024 | 2.24m | 2.30% |
DWS Investments (UK) Ltd.as of 30 Jun 2024 | 2.23m | 2.29% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.76m | 1.80% |